Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis

Table 2

Clinical and laboratory findings in patients with SSc according to serum galectin-9 levels.

	Elevated galectin-9	Normal galectin-9	value
	Age at onset, years (mean ± SD)	53 ± 15		46 ± 11	0.07
Male : female	2 : 49	0 : 11	>0.99
MRSS, points (mean ± SD)	10.2 ± 8.7	6.1 ± 5.6	0.27
Clinical features (%)
dcSSc	53	27	0.19
lcSSc	47	73	0.19
Pitting scars/digital ulcers	37	27	0.73
Contracture of phalanges	47	36	0.74
Diffuse pigmentation	37	9	0.09
Telangiectasia	24	27	>0.99
Organ involvement (%)
Interstitial lung disease	47	27	0.32
Decreased %VC	22	0	0.19
Decreased %DLco	47	27	0.32
Pulmonary hypertension	4	0	>0.99
Esophagus	63	91	0.43
Heart	10	0	0.58
Kidney	4	0	>0.99
Joint	25	18	>0.99
Muscle	20	9	0.67
Laboratory findings (%)
Antitopoisomerase I Abs	39	27	0.52
Anticentromere Abs	43	55	0.52
Elevated ESR	41	0	0.01
Elevated CRP	12	0	0.58

Values were taken on the first visit. versus SSc patients with normal serum galectin-9 levels. SSc: systemic sclerosis; SD: standard deviation; MRSS: modified Rodnan skin score; dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous SSc; VC: vital capacity; DLco: diffusion capacity for carbon monoxide; Abs: antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.